remove body margin top
remove body margin top
bgc
  • ENG
  • 中文
 
谁也不曾料到,2020年,世界被一场突如其来的疫情彻底改变。肆虐全球的新型冠状病毒,已成为人类历史上最危险的病毒之一。
Few predicted a virus of unknown origins could have the power to dramatically change the world we live in. SARS‑CoV‑2, the virus responsible for COVID‑19, has become one of the most dangerous viruses in human history.
接下来你会看到许多病毒“气泡”:每个病毒面积代表确诊人数,内圈的大小代表了死亡人数。密集的气泡提醒着我们,新冠肺炎只是人类众多瘟疫战争中的一役。
In the following pages, you will see illustrated virus bubbles, - the total areas represent the numbers of confirmed cases and their inner cores indicate death tolls. The serried bubbles remind us that COVID-19 is one of numerous plagues humans have lived through.
时间回拨到公元541年,人类历史上有据可考的第一次鼠疫在东罗马帝国爆发。在此后的1400余年里,鼠疫先后两次卷土重来,累计造成至少5000万人死亡。
Back in 541 A.D., the first recorded plague in human history broke out in the Eastern Roman Empire. The epidemic made two comebacks over the next 1,400 years, killing at least 50 million people.
大型传染病的爆发不是孤立事件,这次新冠肺炎再次提醒我们,人类和病毒之间注定有一场无休止的缠斗。
In the course of a long and tangled history, humans have been confronted with a barrage of contagious diseases. The fight between humans and viruses is destined to continue.
这些传染病因何而起?许多病毒宿主都指向了自然界,而新冠肺炎的病毒宿主,至今仍是科学家们日以继夜研究的课题。
A number of diseases have been proven to have a natural origin, with animals as their natural reservoirs. Scientists are researching day and night to understand COVID‑19, but as yet its origins remain unknown.
要攻克新冠肺炎,就得知己知彼。面对这种未知病毒,权威期刊成为全球科学家共享研究成果的前沿阵地之一。
Confronted with the relentless novel coronavirus, scientists are sharing information between institutions and countries via professional medical journals.
截至5月22日,在《新英格兰医学杂志》、《自然》、《柳叶刀》、《科学》、《美国医学会杂志》、《英国医学期刊》这六大顶级科学期刊上,来自中国、美国、英国、德国、新加坡、法国、意大利和西班牙八国的科学家共发表了143篇论文,其中中国科学家发表了67篇,接近发表论文总数的一半。
Scientists from China, the U.S., the UK, Germany, Singapore, France, Italy and Spain have published a total of 143 research papers in the six most prestigious medical journals – The Lancet, Science Magazine, Nature, The Journal of the American Medical Association, British Medical Journal, the New England Journal of Medicine – as of May 22. Chinese medical researchers authored 67 of the studies.
在统计了这六家顶刊发表的143篇论文后,我们发现,新冠肺炎的临床特征、病毒研究、传播模式、隔离控制和接触追踪以及药物试验是科学家们研究的重点。
After analyzing these papers, we found that the research concentrates on five key aspects: Clinical features, virology studies, transmission pattern, quarantine and tracking, as well as drug tests.
在17篇与隔离控制和接触追踪相关的论文中,有7篇直接对中国隔离模式的有效性表示肯定。
Among the 17 articles studying quarantine and tracking, seven clearly affirmed the effectiveness of China's isolation model.
如果说论文为抗击疫情打下了理论基础,那么疫苗的研发则在实践层面提升了人类的防御能力。1月12日,中国向世卫组织提交了新冠病毒基因组序列信息,拉开了全球大规模疫苗研发的序幕。
Research papers can help lay the theoretical foundations for combating COVID‑19. But a vaccine will ultimately be needed.
On January 12, China submitted information about the novel coronavirus genome sequence to the WHO, and global vaccine research and development started soon after.
这里每一根线都表示一款研发中的疫苗,起点是疫苗开始研发的时间。不同颜色代表着不同的研发国家,浅灰色代表多国合作的疫苗。
Each line in this chart represents a vaccine under development, with its length indicating the duration of the process to-date. Colors mark out countries. Light grey lines represent international collaboration on vaccine development.
截至5月22日,据世卫组织不完全统计,中国、美国、德国、新加坡、韩国、英国、法国、意大利、西班牙这九国一共有73款疫苗正在研发。
A total of 73 vaccines were being developed in nine countries. China, the U.S., Germany, Singapore, South Korea, the UK, France, Italy and Spain – as of May 22, according to the WHO.
这里线条的粗细表示疫苗研发的不同进度,四种粗细度分别代表着前期研究、动物试验、一期和二期临床阶段。虚线表示疫苗研发启动时间未知。
The thicknesses of the lines indicate the different progress of vaccine research and development. They represent the exploratory stage and animal testing as well as the phase I and phase II clinical trials. Vaccine developments with unknown start time are shown in dotted lines.
截至5月22日,上述九国共有10款疫苗已获批进入临床试验阶段。
Ten vaccines from the nine countries had been approved for clinical trials as of May 22.
在《柳叶刀》发表的来自中国的陈薇院士团队研制的重组新冠病毒疫苗临床试验结果显示,一期临床108名志愿者全部有显著的细胞免疫反应。这是世界首个新冠疫苗的人体临床数据。
An article published on The Lancet on May 22, authored by Chinese medical scientist Chen Wei, states that the Vaccine Ad5-nCoV first human trial is safe and induces rapid immune response on all the 108 volunteers.
中国与其他国家合作研发了5款疫苗,其中4款与美国合作研发,1款与加拿大合作研发。
China has developed five COVID-19 vaccines in collaboration with other countries. Four of them are with the U.S.
这73款疫苗中的21款涉及多国合作。密集的连线显示出疫苗跨国合作与信息共享的规模是史无前例的。
Twenty one out of the 73 vaccines involve international collaborations. The dense connection lines in this chart illustrate unprecedented global cooperation and information sharing.
临床治疗是抗击新冠肺炎的另一个阵地。截至5月22日,中国共申报345项临床治疗方案,数量位居世界第一。
Clinical treatment is another frontier in the battle against COVID-19. As of May 22, China had declared a total of 345 clinical protocols, ranking first in the world.
纵观采用最多的6类临床治疗方案,皆为老药新用:氯喹类药物主要用于疟疾治疗;瑞德西韦对症埃博拉病毒;血浆疗法曾出现在非典型性肺炎和中东呼吸综合征的治疗中;干细胞疗法对神经类疾病有效;托珠单抗被广泛用于治疗类风湿性关节炎。
We looked at the six most-used types of clinical protocols and found they are not new to humans. Chloroquine is mainly used for malaria treatment; Remdesivir worked against the Ebola virus; plasma therapy has contributed to SARS and MERS treatment; stem cells are effective with neuropathy; Tocilizumab (TCZ) is widely used to treat rheumatic arthritis.
在中国这345项临床治疗方案里,与中医相关的疗法占据了近1/3,达到了111项。由中医药界举办的线上经验分享会,累计网上点击量210万次。
Traditional-Chinese-medicine-related treatment accounts for nearly a third (111) of the 345 protocols of China. A livestreaming event held by traditional Chinese medicine professionals attracted 2.1 million views globally.
论文、疫苗和药物是人们对抗病毒的方法论。这些气泡大小代表着这些科研成果的数量。气泡面积每大一点,战胜新冠病毒的希望就多了一分。
Research papers, vaccines, and clinical medicines provide methodologies to fight COVID-19. The size of these bubbles indicates scientific progress. When the bubble area gets larger, there is more hope for cracking COVID-19.
新冠肺炎不会是人类与病毒的最后一役。凝聚着科学家智慧和奉献精神的科研成果,携手佑护人类健康的全球共识,将为我们提供充足的弹药和坚实的铠甲。人类与病毒之间的战争不止,科学探索和研究不息。
COVID-19 won't be the last battle between humans and viruses. Yet with the ammo and armor of scientists' wisdom and dedication, and the global consensus on protecting human's wellbeing, we shall not fear. Virus wars don't stop; exploration and research will continue.

数据来源:


WHO COVID-19 Database

WHO draft landscape of COVID-19 candidate vaccines

Global Coronavirus COVID-19 Clinical Trial Tracker

*注:


病例、论文、疫苗和临床治疗方案的数据更新到2020年5月22日;

因部分机构未公开披露疫苗研发进程,数据为不完全整理;

各国研发的疫苗数=各国独自研发+合作的疫苗数,因此本报道中疫苗总量超过了73款。


编辑:石韬
责任编辑:王晓南
主编:李受恩,陈姌
数据编辑:周芮
可视化开发:毕建坤
测试工程师:胡荣政,任彧,王鑫
多媒体制作人:徐纪业
制作人:司楠
总监:张施磊
监制:范昀

References:


WHO COVID-19 Database

WHO draft landscape of COVID-19 candidate vaccines

Global Coronavirus COVID-19 Clinical Trial Tracker

Note:


All data of cases, papers, vaccines, and treatments as of May 22.

Since some institutions have not disclosed the progress of their vaccine development, data on vaccines is not comprehensive.

We calculate the vaccines developed by each country as the combination of self-developed vaccines and collaborative vaccines, so the total number of vaccines exceeds 73.

Credits:


Editor: Shi Tao
Managing Editor: Wang Xiaonan
Copy Editor: John Goodrich
Chief Editors: Li Shouen, Chen Ran
Data Editor: Zhou Rui
Interactive Developer: Bi Jiankun
Testing Engineers: Hu Rongzheng, Ren Yu, Wang Xin
Multimedia Producer: Xu Jiye
Producer: Si Nan
Managing Director: Zhang Shilei
Supervisor: Fan Yun

Copyright © 2020 CGTN.
Beijing ICP prepared NO.16065310-3